NeuBase Therapeutics (NeuBase Therapeutics) Book Value per Share : $2.45 (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Book Value per Share?

NeuBase Therapeutics's book value per share for the quarter that ended in Sep. 2023 was $2.45.

During the past 12 months, NeuBase Therapeutics's average Book Value Per Share Growth Rate was -82.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NeuBase Therapeutics was 108.80% per year. The lowest was -86.10% per year. And the median was -14.25% per year.

NeuBase Therapeutics's current price is $0.378. Its book value per share for the quarter that ended in Sep. 2023 was $2.45. Hence, today's PB Ratio of NeuBase Therapeutics is 0.15.

During the past 13 years, the highest P/B Ratio of NeuBase Therapeutics was 9.39. The lowest was 0.00. And the median was 0.00.

NeuBase Therapeutics Book Value per Share Historical Data

The historical data trend for NeuBase Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Book Value per Share Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Book Value per Share

Get a 7-Day Free Trial

162.61

-0.30

11.75

27.03

33.05

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Book Value per Share	Get a 7-Day Free Trial															14.05	10.99	8.55	5.99	2.45

Competitive Comparison of NeuBase Therapeutics's Book Value per Share

For the Biotechnology subindustry, NeuBase Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuBase Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's PB Ratio falls into.

NeuBase Therapeutics Book Value per Share Calculation

NeuBase Therapeutics's Book Value Per Share for the fiscal year that ended in Sep. 2021 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(54.07	-	0.00)	/	1.64
	=	33.05

NeuBase Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(9.14	-	0.00)	/	3.73
	=	2.45

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

NeuBase Therapeutics (NAS:NBSE) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

NeuBase Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

O7P:Germany O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Executives

Symetryx Corp	10 percent owner	2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann	officer: COO	700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei	officer: See Remarks	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall	director	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles	director	2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast	director
Dietrich A Stephan	director, 10 percent owner, officer: President and CEO	213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc	10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801